Pfizer Metsera Bid Heats Up After Court Ruling
Pfizer Metsera bid intensifies as Pfizer matched Novo Nordisk's $10 billion offer and dropped conditions, likely extending the auction and positioning.
KEY TAKEAWAYS
- Pfizer matched Novo Nordisk's $10 billion offer and dropped bid conditions.
- A Delaware court denied Pfizer's request, allowing Metsera to weigh the rival proposal.
- Pfizer signaled plans to raise its offer, implying a potentially protracted auction.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Pfizer Inc. intensified its bid for Metsera, Inc. by matching a rival $10 billion offer from Novo Nordisk A/S, removing conditions from its proposal, and signaling plans to raise the offer. A Delaware Chancery Court denied Pfizer’s request to block Metsera from considering Novo Nordisk’s competing bid, allowing the board to weigh both offers.
Bidding Escalation and Court Decision
Pfizer and Novo Nordisk each submitted bids near $10 billion for Metsera, a biotech focused on obesity therapies. Pfizer notified a Delaware judge on November 5, 2025, that it had removed some conditions from its offer and was preparing to increase the bid to counter Novo Nordisk’s proposal.
On November 6, the Delaware Chancery Court denied Pfizer’s request for a temporary restraining order, permitting Metsera to consider Novo Nordisk’s offer. Metsera’s board was actively evaluating both bids. Novo Nordisk CEO Mike Doustdar expressed confidence in closing the deal, stating, “If we did not feel that we would be able to close the deal, we would not have probably entered the transaction.”
Pipeline and Market Stakes
Metsera’s pipeline includes four clinical-stage obesity programs, featuring both oral and injectable candidates. The obesity drug market is highly competitive, led by Novo Nordisk and Eli Lilly, with Pfizer seeking to expand its presence. The strategic value of Metsera’s programs has driven intense interest from established drugmakers.
No formal financial guidance, transaction terms, or integration plans have been disclosed by Metsera, Pfizer, or Novo Nordisk. The court’s decision and Pfizer’s bid adjustments suggest a potentially prolonged auction that could reshape M&A dynamics in the obesity drug sector.
